U.S. Mortgage Finance Stock News

NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

Did Plug Power’s (PLUG) Higher 2026 Growth Guidance and Narrower Losses Just Shift Its Investment Narrative?

Earlier in August 2026, Plug Power Inc. reported second-quarter results showing revenue of US$178.3 million and a smaller net loss of US$188.21 million, while also increasing its full-year 2026 revenue growth guidance to a range of 15% to 16% based on a stronger commercial backlog. This combination of higher guidance and reduced quarterly losses highlights management’s confidence that its material handling and international electrolyzer projects can support the company’s hydrogen-focused...
NYSE:BOOT
NYSE:BOOTSpecialty Retail

Boot Barn Holdings (BOOT) Could Be 27% Undervalued After Analyst Upgrades

Why analyst sentiment around Boot Barn Holdings matters now Recent analyst upgrades and higher earnings estimates have pushed Boot Barn Holdings (BOOT) into a more favorable ranking, drawing fresh attention to the stock after its recent share price movement. This shift in sentiment is tied to expectations for stronger earnings results, which can influence how investors weigh the company against other retail apparel and footwear stocks. See our latest analysis for Boot Barn Holdings. Over the...
NYSE:JOE
NYSE:JOEReal Estate

Does Anthropologie’s Flagship And Bridal Store at Watersound Transform the Bull Case for St. Joe (JOE)?

The St. Joe Company recently announced that national premium lifestyle retailer Anthropologie has signed a lease for an approximately 9,000 square foot store, including an Anthropologie Weddings bridal shop, at Watersound Town Center, where construction on the new retail building is already underway. This unique combination of a flagship Anthropologie store and an in-store bridal experience, offered only at select locations nationwide, highlights Watersound Town Center’s appeal as a...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Progress Software (PRGS) Launches AI Update, Is The Upside Already Priced In?

Progress Software (PRGS) has drawn fresh attention after launching an AI powered update to its Telerik and Kendo UI platforms and appointing veteran technology leader Bridget Collins as Chief Information Officer earlier in August. See our latest analysis for Progress Software. Progress Software’s recent AI product release and CIO appointment have arrived alongside a sharp 90 day share price return of 48.96% and a 30 day share price return of 17.20%. However, the 1 year total shareholder...
NasdaqGS:SKWD
NasdaqGS:SKWDInsurance

Skyward Specialty Insurance Group (SKWD) Could Be 19% Undervalued After CFO Succession Plan

Skyward Specialty Insurance Group (SKWD) outlined a planned finance leadership transition after Chief Financial Officer Mark Haushill notified the company of his retirement, with Deputy CFO Taryn McHarg set to assume the role. See our latest analysis for Skyward Specialty Insurance Group. Set against this CFO transition, Skyward Specialty Insurance Group’s recent share price performance has been mixed, with a 1 day share price return of 1.84% but a 30 day share price return that declined...
NYSE:RLI
NYSE:RLIInsurance

RLI (RLI) Following Strong Earnings And Capital Returns, Does The Premium Narrative Fit

RLI Corp (RLI) recently confirmed a regular third quarter cash dividend of US$0.18 per share, payable on September 15, 2026. This decision keeps income returns on the stock unchanged for now. See our latest analysis for RLI. RLI shares have gained a 24.39% 90 day share price return, while the 1 year total shareholder return is 3.57%. This suggests recent momentum has strengthened even as valuation commentary points to the stock trading at a premium. If you are reassessing insurance and...
NasdaqGM:ETON
NasdaqGM:ETONPharmaceuticals

Eton Pharmaceuticals (ETON) Returns To Profit As Valuation Debate Gets Harder To Ignore

Eton Pharmaceuticals (ETON) drew investor attention on 13 August 2026 after reporting stronger second quarter earnings and a return to profitability, along with higher full year 2026 revenue guidance of at least US$145 million. See our latest analysis for Eton Pharmaceuticals. Eton Pharmaceuticals’ latest earnings announcement comes after a strong run in the stock, with a 30 day share price return of 49.03% and a 1 year total shareholder return of 266.88%. This adds to very large 3 and 5 year...
NYSE:FCX
NYSE:FCXMetals and Mining

Freeport-McMoRan Stock And 2 Copper Producers Worth Watching At High Bond Yields

Global bond yields are holding near multi year highs, which keeps borrowing costs elevated and squeezes capital intensive projects that rely on cheap debt. That makes existing copper producers with strong balance sheets and low costs even more valuable inventory for the market. This article walks through three stocks from the Top Copper Stocks screener that fit that profile and explains what investors may want to watch next. The three stocks below are a small sample of what rises to the top,...
NasdaqGS:KLIC
NasdaqGS:KLICSemiconductor

Can Kulicke and Soffa (KLIC) Leverage New Leadership To Reframe Its Advanced Packaging Strategy?

Kulicke and Soffa Industries recently appointed Dr. Raj Talluri as Chief Executive Officer, President, and Board member, with his CEO role effective September 1, 2026, and his Board appointment effective August 17, 2026, while interim CEO Lester Wong remains Executive Vice President and Chief Financial Officer. This leadership change brings in a semiconductor veteran whose prior roles at Enovix, Micron, Qualcomm, and Texas Instruments may influence how Kulicke and Soffa prioritizes advanced...
NasdaqGM:APPF
NasdaqGM:APPFSoftware

AppFolio (APPF) Is Up 9.9% After Naming AWS Preferred Cloud Partner For AI-Native Platform

In August 2026, AppFolio, Inc. announced it had named Amazon Web Services as its preferred cloud provider, with its AI-native Performance Platform and Realm suite of AI capabilities running on AWS infrastructure such as Amazon MSK and Amazon Bedrock. This deep collaboration gives AppFolio access to leading foundation models and governance tools while allowing it to refine AWS services to its performance standards, strengthening the technical backbone behind its real estate SaaS...
NYSE:DAL
NYSE:DALAirlines

Delta Air Lines (DAL) Leans On Premium Travel And AI As Valuation Debate Builds

Route cuts, premium focus and AI tools put Delta Air Lines stock in the spotlight Delta Air Lines (DAL) is reshaping its network by cutting lower margin, price sensitive routes, expanding Premium Select cabins and rolling out AI driven pricing and operational tools that aim to sharpen profitability and efficiency. See our latest analysis for Delta Air Lines. At a share price of $82.41, Delta Air Lines has seen short term pressure, with the 7 day share price return down 7.77% and the 30 day...
NasdaqGS:MCBS
NasdaqGS:MCBSBanks

MetroCity Bankshares (MCBS) Faces A Board Shake Up, Is The Stock Fairly Valued?

MetroCity Bankshares (MCBS) drew fresh attention after announcing that vice chairman Don T.P. Leung will resign from the board and multiple key committees in September. The move is raising questions about board structure and risk oversight. See our latest analysis for MetroCity Bankshares. Set against this governance change, MetroCity Bankshares’ recent share price return has cooled over the past month compared with earlier strength, even though the 90 day share price return of 9.12% and 3...
NYSE:NOMD
NYSE:NOMDFood

Do Softer 2026 Results Hint At Limits To Nomad Foods' Margin Story For NOMD?

Nomad Foods Limited has released its second-quarter and half-year 2026 results, reporting sales of €723.7 million and €1.44 billion respectively, with lower net income and earnings per share than the same periods a year earlier. The simultaneous decline in both sales and profitability across the quarter and first half of 2026 highlights pressure on Nomad Foods’ operational performance and cost management. Next, we will examine how this softer revenue and earnings performance shapes Nomad...
NYSE:PLGO
NYSE:PLGOInsurance

Why Everyone Is Watching Pelagos Insurance Capital (PLGO) Now

Why Pelagos Insurance Capital Stock Is Back on Investors’ Radar Pelagos Insurance Capital (PLGO) drew fresh attention after reporting second quarter and first half 2026 results that showed higher revenue, a swing to net profit and continued execution on its share repurchase program. See our latest analysis for Pelagos Insurance Capital. Pelagos Insurance Capital’s earnings rebound and ongoing buybacks have come alongside a 24.05% year to date share price return and a 41.39% total shareholder...
NasdaqGS:VCTR
NasdaqGS:VCTRCapital Markets

Victory Capital Holdings (VCTR) Rallies Above Fair Value, Is The Upside Already Priced In?

Victory Capital Holdings stock update Victory Capital Holdings (VCTR) drew fresh attention after its recent share price move, with the stock closing at $115.63. Investors are weighing this level against the company’s latest financial profile and recent return history. See our latest analysis for Victory Capital Holdings. The recent move to a US$115.63 share price comes after a strong run, with an 18.96% 1 month share price return and an 80.39% year to date share price return, alongside a 5...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

How Marex’s Stronger H1 Earnings and Steady Dividend Policy Will Impact Marex Group (MRX) Investors

Marex Group Limited recently reported half-year 2026 results showing net income of US$268 million and significantly higher earnings per share versus a year earlier, while also affirming a quarterly dividend of US$0.16 per share payable on September 9, 2026. Alongside stronger profitability, Marex’s decision to maintain its regular cash dividend sends a clear signal about management’s confidence in the company’s financial position and cash-generation capacity. We’ll now examine how Marex’s...
NYSE:TDG
NYSE:TDGAerospace & Defense

TransDigm Group (TDG) Faces A Fair Value Debate, Is The 21% Upside Convincing?

TransDigm Group stock performance snapshot TransDigm Group (TDG) has drawn investor attention after a mixed share price pattern. The stock is up about 1.7% today, yet it is down over the past week, month, and past 3 months. Year to date, TransDigm Group has declined about 11.6%, with the 1 year total return down roughly 8.9%. Longer term holders have seen higher total returns over 3 and 5 years, based on the data provided. The company last closed at US$1,200.35, giving TransDigm Group an...
NasdaqGS:SYRE
NasdaqGS:SYREBiotechs

Should Spyre’s New Dual-Pathway HS Strategy and SKYLIGHT Trial Design Reshape the Spyre Therapeutics (SYRE) Narrative?

In August 2026, Spyre Therapeutics announced SPY772, a new preclinical combination program pairing its long-acting anti-TL1A antibody SPY072 with the novel long-acting anti-IL-17A/F antibody SPY007, and reported the start of SKYLIGHT, a randomized, placebo-controlled Phase 2 proof-of-concept trial in approximately 150 adults with moderate-to-severe Hidradenitis Suppurativa receiving background bimekizumab therapy, with topline data planned for late 2027 or early 2028. This dual-inhibition...
NYSE:H
NYSE:HHospitality

How A US$50 Million Guyana Push At Hyatt Hotels (H) Has Changed Its Investment Story

Hyatt Hotels Corporation and RJR Investments & Holdings Inc. recently added Atlantic Suites Hotel in Georgetown, Guyana to the Hyatt portfolio as its first affiliated property in the country, with plans for an approximately US$50 million expansion that will convert it into Hyatt Regency Georgetown Guyana by 2028. This move extends Hyatt’s reach into an emerging Latin America and Caribbean market while deepening the World of Hyatt ecosystem through future loyalty integration and a planned...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports Valuation

Celcuity (CELC) reported second quarter 2026 results that showed a wider net loss, an update that can influence how investors evaluate the stock’s risk profile and long term development plans. See our latest analysis for Celcuity. Celcuity’s latest earnings report, which showed a larger net loss, arrived as the stock posted a 1 month share price return of 13.21% but a 3 month share price decline of 32.34%. The 1 year total shareholder return of 78.42% highlights how longer term momentum has...
NYSE:HLF
NYSE:HLFPersonal Products

Did Herbalife's (HLF) Revenue Beat and Weak Guidance Just Reframe Its Profitability Trade-offs?

Earlier this month, Herbalife reported quarterly revenues of US$1.33 billion, up 5.4% year on year and 1.5% above analyst expectations, but significantly missed earnings-per-share estimates and issued relatively weak forward guidance. This combination of stronger sales but softer profitability and outlook highlights an ongoing tension between Herbalife’s top-line momentum and its ability to convert that into earnings growth. We’ll now examine how Herbalife’s revenue beat but weak guidance...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

Zscaler (ZS) Expands Carahsoft Tie Up As Zero Trust Optimism Tests Fair Value

Zscaler (ZS) is back in focus after it expanded its partnership with Carahsoft to push its Zero Trust Exchange deeper into U.S. small and mid-sized businesses, a move that intersects with stronger interest in SASE leaders. See our latest analysis for Zscaler. The partnership news lands after a mixed run for Zscaler, with the share price gaining 27.7% over the last 30 days but the year to date share price return declining 17.6%. Over the last year, the total shareholder return is down 33.31%,...
NYSE:BHVN
NYSE:BHVNBiotechs

Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?

Biohaven earnings update and what it means for investors Biohaven (BHVN) reported second quarter 2026 results that showed a reduced net loss of US$137.31 million. Loss per share from continuing operations was US$0.91, compared with US$1.94 a year earlier. For the first half of 2026, Biohaven reported a net loss of US$267.84 million, with basic loss per share from continuing operations of US$1.80, compared with US$4.11 in the prior year period. See our latest analysis for Biohaven. Biohaven’s...
NYSE:QGEN
NYSE:QGENLife Sciences

How FDA Clearance of QIAstat-Dx Sepsis Panel Will Impact Qiagen (QGEN) Investors

In August 2026, QIAGEN announced that the U.S. FDA had cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx bloodstream infection panel to receive FDA clearance, expanding the platform’s U.S. coverage to four infectious disease areas and delivering one-hour pathogen and resistance marker results from positive blood cultures. This clearance not only broadens QIAGEN’s infectious disease testing menu on a single integrated platform, but also positions the company to address the...